In silico detection of SARS-CoV-2 specific B-cell epitopes and validation in ELISA for serological diagnosis of COVID-19

David Kim; Lauren Carter; Neil King; Ivan Anishchenko; Lynn K Barrett; Justin K Craig; Logan Tillery; Roger Shek; David M Koelle; Anna Wald; Jim Boonyaratanakornkit; Nina Isoherranen; Alexander L Greninger; Keith R Jerome; Helen Chu; Wesley C Van Voorhis.
Preprint en Inglés | PREPRINT-BIORXIV | ID: ppbiorxiv-111526

Documentos relacionados

  1. In silico detection of SARS-CoV-2 specific B-cell epitopes and validation in ELISA for serological diagnosis of COVID-19.
  2. The neutralizing breadth of antibodies targeting diverse conserved epitopes between SARS-CoV and SARS-CoV-2.
  3. Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins.
  4. Comprehensive mapping of SARS-CoV-2 peptide epitopes for development of a highly sensitive serological test for total and neutralizing antibodies.
  5. Evaluation of three fully-automated SARS-CoV-2 antibody assays.
  6. Deep mutational scanning identifies SARS-CoV-2 Nucleocapsid escape mutations of currently available rapid antigen tests.
  7. Dissection of Antibody Responses of Gam-COVID-Vac-Vaccinated Subjects Suggests Involvement of Epitopes Outside RBD in SARS-CoV-2 Neutralization.
  8. Plasmonically Enhanced Ultrasensitive Epitope-Specific Serologic Assay for COVID-19.
  9. Development and evaluation of multi-epitope protein p72 (MeP72) for the serodiagnosis of African swine fever.
  10. Neutralization of SARS-CoV-2 requires antibodies against conformational receptor-binding domain epitopes.